



## **Painless future: new members for Board of Directors, funding and clinical results outlook**

**Schlieren (Zurich), Switzerland, April 27, 2010.** The shareholders of Neurotune AG, a Swiss biopharmaceutical company, have elected **Dr. Anders Härfstrand** and **Heinrich Rotach** as new members of the board of directors at their annual general assembly on April 21, 2010. Anders Härfstrand is a medical doctor with extensive experience in neuropharmacology and an excellent track record as executive director in the pharmaceutical industry (e.g. Pharmacia, Pfizer, Serono). Heinrich Rotach has extensive experience in the financial industry (e.g. UBS). Neurotune will strongly profit from their knowhow and their standing in the biotech industry and is highly pleased to have them on board.

In March, Neurotune AG has also expanded its capital base by closing a **capital raise** with its current investors, among them Neurotune's major shareholder CC Private Equity Partners, as well as additional private investors. This will allow Neurotune to further advance its portfolio in pain and sarcopenia. To this end, the lead compound of Neurotune, NT-11624, is currently in clinical phase IIa in South Africa for antiretroviral treatment-induced pain in AIDS patients. In January 2010, Neurotune had completed recruitment of more than 100 patients. The trial was finished in March 2010. The extraordinarily low drop out rate of 4% clearly indicates that NT-11624 is well tolerated as predicted from previous phase I data. Currently the **clinical data of the phase IIa** are under statistical analysis with the top line results expected middle of 2010. Furthermore, **compassionate use** has been requested and granted by the South African regulatory authorities.

### **CONTACT**

#### **Neurotune AG**

Dr. Bruno Oesch  
CEO  
Wagistrasse 27a  
8952 Schlieren  
Switzerland  
Phone +41 44 200 21 95  
Fax +41 44 200 21 80  
ceo@neurotune.com

#### **Media enquiries**

Dr. Holger Bengs  
Biotech Consulting  
Phone +49 69 6199 4273  
Fax +49 69 6199 4249  
info@holgerbengs.de

## **ABOUT NEUROTUNE AG**

Neurotune was incorporated in January 2005 and has its domicile in Schlieren, Switzerland. Neurotune develops small-molecular drugs and biologicals to treat disorders of the human nervous system, i.e. neuropathic pain and sarcopenia.

## **ABOUT NEUROPATHIC PAIN**

Neuropathic pain is a type of chronic pain. It is a result of damage to the nervous system following infection, disease, injury, and certain medications. Neuropathic pain serves no protective function. Instead of functioning properly to warn of tissue injury, the nervous system malfunctions and becomes the cause of the pain. Neuropathic pain can continue for months or years and is often described as "burning," "electric," "tingling," or "shooting."

This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the neurotune's shelf registration statement and the registered direct offering. For further information regarding these and other risks related to neurotune's business, investors should consult neurotune.